NFKB1 and Miyoshi myopathy: Immunomodulator that inhibits NF-κB pathway, activates caspase and promotes apoptosis [5]. It is the first-line drug for newly discovered MM. It is mainly involved in immune regulation, suppressing angiogenesis and proliferation.